BTIG analyst Sam Eiber kept a buy rating on Merit Medical Systems while cutting its price target ahead of Medicare payment changes. The adjustment was reported on April 13, and the analyst said the move reflects expectations that the upcoming policy shift could affect the company's revenue mix.

The change matters because Merit Medical, a maker of medical devices, is sensitive to reimbursement rates that drive hospital purchasing decisions. A lower price target suggests the firm may face tighter margins, but maintaining a buy rating signals confidence that the stock can still outperform the broader market as the company adapts to new payment structures.

Eiber first initiated coverage of Merit Medical with a buy recommendation on February 6, 2026, according to a separate report. That initial coverage set the baseline for the firm's valuation and highlighted the company's growth prospects in minimally invasive procedures. By revisiting the model in April, BTIG aims to position the stock ahead of the expected Medicare changes, which could reshape pricing dynamics for many device manufacturers.

The analyst's price forecast suggests a 33.68% upside from current levels, underscoring the belief that Merit Medical can capture market share despite the policy headwinds. While the price target was reduced, the upside estimate reflects a blend of the company's product pipeline, recent earnings strength, and the potential for cost efficiencies as it navigates the new reimbursement landscape.

Investors will watch how Merit Medical implements strategic initiatives to offset any revenue pressure from Medicare. The firm has announced plans to expand its portfolio of catheter and guidewire technologies, which could bolster sales in both U.S. and international markets. Additionally, the company is exploring partnerships to enhance its distribution network, a move that may mitigate the impact of slower payment cycles.

Overall, BTIG's adjusted outlook signals a nuanced view: the stock remains a buy, but analysts expect a more measured performance trajectory as Medicare reforms take effect. Market participants should factor in both the upside potential and the revised target when evaluating Merit Medical's position within the healthcare sector.

“BTIG analyst Sam Eiber kept a Buy rating on Merit Medical Systems.”

The revised rating suggests investors can still expect growth from Merit Medical, but they should temper expectations as Medicare reforms may compress margins. The upside estimate indicates room for price appreciation if the company successfully leverages its product pipeline and cost‑saving initiatives, making the stock a cautious yet potentially rewarding play in the medical‑device arena.